Premium
Posaconazole for treatment of refractory invasive fungal disease
Author(s) -
Notheis G.,
Tarani L.,
Costantino F.,
Jansson A.,
Rosenecker J.,
Friederici D.,
Belohradsky B. H.,
Reinhardt D.,
Seger R.,
Schweinitz D. V.,
Wintergerst Uwe
Publication year - 2006
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/j.1439-0507.2006.01301.x
Subject(s) - posaconazole , refractory (planetary science) , medicine , zygomycosis , mucormycosis , mucor , antifungal , aspergillosis , girl , disease , mycosis , dermatology , diabetes mellitus , aspergillus nidulans , invasive candidiasis , aspergillus , amphotericin b , surgery , biology , immunology , microbiology and biotechnology , fluconazole , endocrinology , astrobiology , biochemistry , genetics , gene , mutant
Summary Invasive fungal infections are usually associated with immunocompromised states About 40–60% of these patients are refractory to standard antifungal therapy We describe the effect of posoconazole in the treatment of a 12 years‐old girl with uncontrolled diabetes mellitus with life‐threatening cerebral mucor mycosis and a 4 year old girl boy with chronic granulomatous disease presenting with invasive Aspergillus nidulans infection.